CEO Kevin Lee was paid $6,341,473 in fiscal year 2025, ↑ up 30.6% from fiscal year 2024, the 37th percentile of its disclosed peer group (SEC filing 0001104659-26-046806 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$6,341,473 ↑ Kevin Lee total, FY2025 | 37th CEO pay percentile vs peers | — CEO-to-median pay ratio | 98.42% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
BCYC's next annual pay disclosure, estimated April 21, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Kevin Lee | $862,339 | $0 | $1,724,800 | $2,961,297 | $543,642 | $0 | $249,395 | $6,341,473 |
| Chief Executive Officer | ||||||||
| Michael Skynner | 612,471 | 0 | 490,000 | 836,470 | 319,355 | 0 | 68,714 | 2,327,010 |
| Chief Technology Officer (2025); Chief Scientific Officer (effective January 1, 2026) | ||||||||
| Alistair Milnes | 578,189 | 0 | 490,000 | 836,470 | 322,520 | 0 | 65,245 | 2,292,424 |
| Chief Operating Officer (2025); Chief Corporate Development Officer (effective March 17, 2026) | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Kevin Lee | $6,341,473 | $4,857,218 | $5,540,400 | ↑ +1,484,255 |
| Michael Skynner | 2,327,010 | — | — | — |
| Alistair Milnes | 2,292,424 | 2,591,573 | 2,084,264 | ↓ −299,149 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Bicycle Therapeutics's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper BCYC reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
Each company listed discloses BCYC in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named BCYC in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Alessandro Riva, M.D | Independent Director | $322,657 |
| Charles Swanton, M.D., Ph.D., FRS, FMedSci, FRCP | Independent Director | $280,948 |
| Felix J. Baker, Ph.D | Chair of the Board | $234,929 |
| Herve Hoppenot | Independent Director | $229,236 |
| Janice Bourque, MBA | Former director (through FY2025) | $304,661 |
| Jose-Carlos Gutierrez-Ramos, Ph.D | Independent Director | $370,578 |
| Pierre Legault, MBA, CPA | Former director (through FY2025) | $546,875 |
| Richard Kender, MBA | Former director (through FY2025) | $265,200 |
| Roger Dansey, M.D | Independent Director | $246,859 |
| Sir Gregory Winter, FRS | Former director (through FY2025) | $272,683 |
| Stephen Sands, MBA | Independent Director | $273,174 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Jennifer Scott Perry | Chief Operating Officer | 2026-07-02 | D | 1,036 | $4 | $4,424 | Common | Form 4 ↗ |
| Travis Alvin Thompson | Chief Financial Officer | 2026-07-02 | D | 819 | 4 | 3,497 | Common | Form 4 ↗ |
| Kevin Lee | Director | 2026-07-02 | D | 5,905 | 4 | 25,214 | Common | Form 4 ↗ |
| Michael Skynner | CHIEF SCIENTIFIC OFFICER | 2026-07-02 | D | 1,859 | 4 | 7,938 | Common | Form 4 ↗ |
| Hannay Michael Charles Ferguson | CHIEF PROD & SUPPLY CHAIN OFF | 2026-07-02 | D | 1,506 | 4 | 6,431 | Common | Form 4 ↗ |
| Michael Skynner | CHIEF SCIENTIFIC OFFICER | 2026-07-06 | D | 532 | 4 | 2,293 | Common | Form 4 ↗ |
| Kevin Lee | Director | 2026-07-06 | D | 1,737 | 4 | 7,486 | Common | Form 4 ↗ |
| Jennifer Scott Perry | Chief Operating Officer | 2026-07-06 | D | 333 | 4 | 1,445 | Common | Form 4 ↗ |
| Jennifer Scott Perry | Chief Operating Officer | 2026-07-06 | D | 43 | 4 | 185 | Common | Form 4 ↗ |
| Travis Alvin Thompson | Chief Financial Officer | 2026-07-06 | D | 104 | 4 | 448 | Common | Form 4 ↗ |
| Hannay Michael Charles Ferguson | CHIEF PROD & SUPPLY CHAIN OFF | 2026-07-06 | D | 255 | 4 | 1,099 | Common | Form 4 ↗ |
| Jennifer Scott Perry | Chief Operating Officer | 2026-07-15 | A | 60,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Hannay Michael Charles Ferguson | CHIEF PROD & SUPPLY CHAIN OFF | 2026-07-15 | A | 60,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Travis Alvin Thompson | Chief Financial Officer | 2026-07-15 | A | 60,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Skynner | CHIEF SCIENTIFIC OFFICER | 2026-07-15 | A | 60,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Lee | Director | 2026-10-02 | D | 6,167 | 3 | 21,399 | Common | Form 4 ↗ |
| Michael Skynner | CHIEF SCIENTIFIC OFFICER | 2026-10-02 | D | 1,942 | 3 | 6,739 | Common | Form 4 ↗ |
| Jennifer Scott Perry | Chief Operating Officer | 2026-10-02 | D | 1,094 | 3 | 3,796 | Common | Form 4 ↗ |
| Robert Charles Swanton | Director | 2026-10-02 | D | 3,431 | 3 | 11,906 | Common | Form 4 ↗ |
| Hannay Michael Charles Ferguson | CHIEF PROD & SUPPLY CHAIN OFF | 2026-10-02 | D | 1,572 | 3 | 5,455 | Common | Form 4 ↗ |
| Travis Alvin Thompson | Chief Financial Officer | 2026-10-02 | D | 893 | 3 | 3,099 | Common | Form 4 ↗ |
| Jennifer Scott Perry | Chief Operating Officer | 2026-10-05 | D | 326 | 4 | 1,232 | Common | Form 4 ↗ |
| Jennifer Scott Perry | Chief Operating Officer | 2026-10-05 | D | 30 | 4 | 107 | Common | Form 4 ↗ |
| Kevin Lee | Director | 2026-10-05 | D | 1,638 | 4 | 5,848 | Common | Form 4 ↗ |
| Michael Skynner | CHIEF SCIENTIFIC OFFICER | 2026-10-05 | D | 503 | 4 | 1,796 | Common | Form 4 ↗ |
| Jennifer Scott Perry | Chief Operating Officer | 2026-10-05 | D | 326 | 4 | 1,232 | Common | Form 4 ↗ |
| Jennifer Scott Perry | Chief Operating Officer | 2026-10-05 | D | 80 | 4 | 285 | Common | Form 4 ↗ |
| Hannay Michael Charles Ferguson | CHIEF PROD & SUPPLY CHAIN OFF | 2026-10-05 | D | 242 | 4 | 864 | Common | Form 4 ↗ |
| Travis Alvin Thompson | Chief Financial Officer | 2026-10-05 | D | 79 | 4 | 282 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Michael Skynner | OPTION | — | — | — | — | — | $836,470 |
| Alistair Milnes | RSU | — | — | — | — | — | 490,000 |
| Kevin Lee | RSU | — | — | — | — | — | 1,724,800 |
| Michael Skynner | RSU | — | — | — | — | — | 490,000 |
| Kevin Lee | OPTION | — | — | — | — | — | 2,961,297 |
| Alistair Milnes | OPTION | — | — | — | — | — | 836,470 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Michael Skynner | $490,000 | $0 | $836,470 | 0.0% |
| Alistair Milnes | 490,000 | 0 | 836,470 | 0.0% |
| Kevin Lee | 1,724,800 | 0 | 2,961,297 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Alistair Milnes | RSU | 938 | — | $6,641 |
| Michael Skynner | Option | 87,000 | 14 | — |
| Alistair Milnes | Option | 2,084 | 60.87 | — |
| Kevin Lee | RSU | 123,200 | — | 872,256 |
| Kevin Lee | RSU | 43,313 | — | 306,656 |
| Kevin Lee | RSU | 3,125 | — | 22,125 |
| Michael Skynner | Option | 625 | 60.87 | — |
| Kevin Lee | Option | 308,000 | 14 | — |
| Michael Skynner | RSU | 15,750 | — | 111,510 |
| Michael Skynner | Option | 29,167 | 18.08 | — |
| Alistair Milnes | RSU | 35,000 | — | 247,800 |
| Michael Skynner | RSU | 5,469 | — | 38,721 |
| Michael Skynner | RSU | 938 | — | 6,641 |
| Michael Skynner | Option | 9,480 | 29.6 | — |
| Alistair Milnes | RSU | 5,469 | — | 38,721 |
| Michael Skynner | RSU | 35,000 | — | 247,800 |
| Kevin Lee | Option | 2,084 | 60.87 | — |
| Kevin Lee | Option | 80,730 | 18.08 | — |
| Alistair Milnes | Option | 87,000 | 14 | — |
| Alistair Milnes | Option | 9,480 | 29.6 | — |
| Alistair Milnes | RSU | 21,938 | — | 155,321 |
| Kevin Lee | Option | 31,146 | 29.6 | — |
| Alistair Milnes | Option | 40,105 | 18.08 | — |
| Kevin Lee | RSU | 17,969 | — | 127,221 |
The Compensation Committee believes that the most effective compensation program is one that rewards sustainable value creation for our shareholders, by delivering strong company performance, as well as tangible progress towards achieving our mission.
| CEO STI target (% of salary) | 65% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-17 | 48,748,743 | 785,032 | 163,133 | 98.42% | Passed |
| 2025 | 2025-06-17 | 47,287,428 | 1,743,008 | 104,623 | 96.45% | Passed |
| 2024 | 2024-05-16 | 36,186,115 | 1,202,477 | 9,515 | 96.78% | Passed |
| 2023 | 2023-06-13 | 26,083,084 | 1,965,019 | 8,818 | 92.99% | Passed |
| 2022 | 2022-06-27 | 23,466,799 | 276,755 | 1,801,179 | 98.83% | Passed |
| 2021 | 2021-06-28 | 19,098,902 | 556,551 | 1,969,184 | 97.17% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-17 | 98.42%a |
| 2025 | 2025-06-17 | 96.45%b |
| 2024 | 2024-05-16 | 96.78%c |
a. Approved under the standard stated in the filing — “6 Table of Contents What is an "abstention" and how would it affect the vote? An abstention is not a vote in law and will not be counted in the calculation of the proportion of the votes for or against a particular resolution.”.
b. Approved under the standard stated in the filing — “6 Table of Contents What is an "abstention" and how would it affect the vote? An abstention is not a vote in law and will not be counted in the calculation of the proportion of the votes for or against a particular resolution.”.
c. Approved under the standard stated in the filing — “What is an "abstention" and how would it affect the vote? An abstention is not a vote in law and will not be counted in the calculation of the proportion of the votes for or against a particular resolution.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Pierre Legault, MBA, CPANot independent · Not standing for re-election · Departed during FY | $28,695 | $175,000 | $240,365 | $0 | $102,815 | $546,875 |
| Jose-Carlos Gutierrez-Ramos, Ph.DIndependent · Nominating and Corporate Governance | 90,000 | 87,500 | 120,183 | 0 | 72,895 | 370,578 |
| Alessandro Riva, M.DIndependent · Audit · Compensation · Newly elected | 54,173 | 115,000 | 153,484 | 0 | 0 | 322,657 |
| Janice Bourque, MBAIndependent · Audit · Compensation (Chair) · Not standing for re-election · Departed during FY | 95,000 | 87,500 | 120,183 | 0 | 1,978 | 304,661 |
| Charles Swanton, M.D., Ph.D., FRS, FMedSci, FRCPIndependent · Nominating and Corporate Governance · Newly elected | 24,715 | 93,250 | 121,733 | 0 | 41,250 | 280,948 |
| Stephen Sands, MBAIndependent · Audit (Chair) | 91,981 | 75,502 | 103,713 | 0 | 1,978 | 273,174 |
| Sir Gregory Winter, FRSIndependent · Nominating and Corporate Governance · Not standing for re-election · Departed during FY | 65,000 | 87,500 | 120,183 | 0 | 0 | 272,683 |
| Richard Kender, MBAIndependent · Compensation · Nominating and Corporate Governance · Not standing for re-election · Departed during FY | 55,539 | 87,500 | 120,183 | 0 | 1,978 | 265,200 |
| Roger Dansey, M.DIndependent · Audit · Newly elected | 22,077 | 89,500 | 116,082 | 0 | 19,200 | 246,859 |
| Felix J. Baker, Ph.DIndependent · Board Chair · Nominating and Corporate Governance | 88,711 | 61,600 | 84,618 | 0 | 0 | 234,929 |
| Herve HoppenotIndependent · Audit · Newly elected | 23,654 | 89,500 | 116,082 | 0 | 0 | 229,236 |
| Kevin Lee, Ph.D., MBAEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | $135,000 |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $639,545 |
| Equity awards (grant-date value) | $1,049,352 |
| All other compensation | $242,094 |
| Total cost of the board | $1,930,991 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Bicycle Therapeutics | 2025 | Kevin Lee | $862,339 | $1,724,800 | $2,961,297 | $543,642 | $6,341,473 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Kevin Lee | DEF 14A | 2026-04-22 | 0001104659-26-046806 | Section “Summary Compensation Table”. As printed: 6,341,473. Filing ↗machine: t83 · r5 · c14 · span 491024–491033 |
| 2 | Section 01, Michael Skynner | DEF 14A | 2026-04-22 | 0001104659-26-046806 | Section “Summary Compensation Table”. As printed: 2,327,010. Filing ↗machine: t83 · r7 · c14 · span 499366–499375 |
| 3 | Section 01, Alistair Milnes | DEF 14A | 2026-04-22 | 0001104659-26-046806 | Section “Summary Compensation Table”. As printed: 2,292,424. Filing ↗machine: t83 · r9 · c14 · span 507821–507830 |
| 4 | Section 03, Michael Skynner OPTION | DEF 14A | 2026-04-22 | 0001104659-26-046806 | Section “Summary Compensation Table” · grants of plan-based awards table. Filing ↗machine: t83 · r7 · c6 · span 496956–496963 |
| 5 | Section 03, Alistair Milnes RSU | DEF 14A | 2026-04-22 | 0001104659-26-046806 | Section “Summary Compensation Table” · grants of plan-based awards table. Filing ↗machine: t83 · r9 · c8 · span 505971–505978 |
| 6 | Section 03, Kevin Lee RSU | DEF 14A | 2026-04-22 | 0001104659-26-046806 | Section “Summary Compensation Table” · grants of plan-based awards table. Filing ↗machine: t83 · r5 · c8 · span 489171–489180 |
| 7 | Section 03, Michael Skynner RSU | DEF 14A | 2026-04-22 | 0001104659-26-046806 | Section “Summary Compensation Table” · grants of plan-based awards table. Filing ↗machine: t83 · r7 · c8 · span 497516–497523 |
| 8 | Section 03, Kevin Lee OPTION | DEF 14A | 2026-04-22 | 0001104659-26-046806 | Section “Summary Compensation Table” · grants of plan-based awards table. Filing ↗machine: t83 · r5 · c6 · span 488609–488618 |
| 9 | Section 03, Alistair Milnes OPTION | DEF 14A | 2026-04-22 | 0001104659-26-046806 | Section “Summary Compensation Table” · grants of plan-based awards table. Filing ↗machine: t83 · r9 · c6 · span 505411–505418 |
| 10 | Section 07, pay ratio | DEF 14A | 2026-04-22 | 0001104659-26-046806 | Section “CEO Pay Ratio”. As printed: —. Filing ↗ |
| 11 | Section 08, Pierre Legault, MBA, CPA | DEF 14A | 2026-04-22 | 0001104659-26-046806 | Section “Director Compensation”. As printed: 546,875. Filing ↗machine: t65 · r10 · c10 · span 394040–394213 |
| 12 | Section 08, Jose-Carlos Gutierrez-Ramos, Ph.D | DEF 14A | 2026-04-22 | 0001104659-26-046806 | Section “Director Compensation”. As printed: 370,578. Filing ↗machine: t65 · r7 · c10 · span 385120–385293 |
| 13 | Section 08, Alessandro Riva, M.D | DEF 14A | 2026-04-22 | 0001104659-26-046806 | Section “Director Compensation”. As printed: 322,657. Filing ↗machine: t65 · r11 · c10 · span 396916–397089 |
| 14 | Section 08, Janice Bourque, MBA | DEF 14A | 2026-04-22 | 0001104659-26-046806 | Section “Director Compensation”. As printed: 304,661. Filing ↗machine: t65 · r5 · c10 · span 379068–379241 |
| 15 | Section 08, Charles Swanton, M.D., Ph.D., FRS, FMedSci, FRCP | DEF 14A | 2026-04-22 | 0001104659-26-046806 | Section “Director Compensation”. As printed: 280,948. Filing ↗machine: t65 · r13 · c10 · span 403018–403191 |
| 16 | Section 08, Stephen Sands, MBA | DEF 14A | 2026-04-22 | 0001104659-26-046806 | Section “Director Compensation”. As printed: 273,174. Filing ↗machine: t65 · r12 · c10 · span 399995–400168 |
| 17 | Section 08, Sir Gregory Winter, FRS | DEF 14A | 2026-04-22 | 0001104659-26-046806 | Section “Director Compensation”. As printed: 272,683. Filing ↗machine: t65 · r14 · c10 · span 406041–406214 |
| 18 | Section 08, Richard Kender, MBA | DEF 14A | 2026-04-22 | 0001104659-26-046806 | Section “Director Compensation”. As printed: 265,200. Filing ↗machine: t65 · r9 · c10 · span 390992–391165 |
| 19 | Section 08, Roger Dansey, M.D | DEF 14A | 2026-04-22 | 0001104659-26-046806 | Section “Director Compensation”. As printed: 246,859. Filing ↗machine: t65 · r6 · c10 · span 382232–382405 |
| 20 | Section 08, Felix J. Baker, Ph.D | DEF 14A | 2026-04-22 | 0001104659-26-046806 | Section “Director Compensation”. As printed: 234,929. Filing ↗machine: t65 · r4 · c10 · span 376320–376493 |
| 21 | Section 08, Herve Hoppenot | DEF 14A | 2026-04-22 | 0001104659-26-046806 | Section “Director Compensation”. As printed: 229,236. Filing ↗machine: t65 · r8 · c10 · span 388120–388293 |
| 22 | Section 08, Kevin Lee, Ph.D., MBA | DEF 14A | 2026-04-22 | 0001104659-26-046806 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 23 | Section 02, Jennifer Scott Perry 2026-07-02 | Form 4 | 2026-07-07 | 0002119908-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, Travis Alvin Thompson 2026-07-02 | Form 4 | 2026-07-07 | 0001983944-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, Kevin Lee 2026-07-02 | Form 4 | 2026-07-07 | 0001776938-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Michael Skynner 2026-07-02 | Form 4 | 2026-07-07 | 0001776582-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Hannay Michael Charles Ferguson 2026-07-02 | Form 4 | 2026-07-07 | 0002015378-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Michael Skynner 2026-07-06 | Form 4 | 2026-07-07 | 0001776582-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Kevin Lee 2026-07-06 | Form 4 | 2026-07-07 | 0001776938-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Jennifer Scott Perry 2026-07-06 | Form 4 | 2026-07-07 | 0002119908-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Jennifer Scott Perry 2026-07-06 | Form 4 | 2026-07-07 | 0002119908-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Travis Alvin Thompson 2026-07-06 | Form 4 | 2026-07-07 | 0001983944-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Hannay Michael Charles Ferguson 2026-07-06 | Form 4 | 2026-07-07 | 0002015378-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Jennifer Scott Perry 2026-07-15 | Form 4 | 2026-07-17 | 0002119908-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Hannay Michael Charles Ferguson 2026-07-15 | Form 4 | 2026-07-17 | 0002015378-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Travis Alvin Thompson 2026-07-15 | Form 4 | 2026-07-17 | 0001983944-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Michael Skynner 2026-07-15 | Form 4 | 2026-07-17 | 0001776582-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Kevin Lee 2026-10-02 | Form 4 | 2026-10-06 | 0001776938-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Michael Skynner 2026-10-02 | Form 4 | 2026-10-06 | 0001776582-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Jennifer Scott Perry 2026-10-02 | Form 4 | 2026-10-06 | 0002119908-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Robert Charles Swanton 2026-10-02 | Form 4 | 2026-10-06 | 0002079922-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Hannay Michael Charles Ferguson 2026-10-02 | Form 4 | 2026-10-06 | 0002015378-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Travis Alvin Thompson 2026-10-02 | Form 4 | 2026-10-06 | 0001983944-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Jennifer Scott Perry 2026-10-05 | Form 4 | 2026-10-07 | 0002119908-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Jennifer Scott Perry 2026-10-05 | Form 4 | 2026-10-07 | 0002119908-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Kevin Lee 2026-10-05 | Form 4 | 2026-10-06 | 0001776938-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Michael Skynner 2026-10-05 | Form 4 | 2026-10-06 | 0001776582-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Jennifer Scott Perry 2026-10-05 | Form 4 | 2026-10-06 | 0002119908-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Jennifer Scott Perry 2026-10-05 | Form 4 | 2026-10-06 | 0002119908-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Hannay Michael Charles Ferguson 2026-10-05 | Form 4 | 2026-10-06 | 0002015378-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Travis Alvin Thompson 2026-10-05 | Form 4 | 2026-10-06 | 0001983944-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 06, 2026 vote | Form 8-K | 2026-06-18 | 0001104659-26-075451 | Item 5.07 · say-on-pay result. As reported: 98.42% (votes for as printed: 48,748,743). Filing ↗ |
| 53 | Section 06, 2025 vote | Form 8-K | 2025-06-17 | 0001104659-25-060316 | Item 5.07 · say-on-pay result. As reported: 96.45% (votes for as printed: 47,287,428). Filing ↗ |
| 54 | Section 06, 2024 vote | Form 8-K | 2024-05-16 | 0001104659-24-062503 | Item 5.07 · say-on-pay result. As reported: 96.78% (votes for as printed: 36,186,115). Filing ↗ |
| 55 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 56 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 57 | Section 09b board cost (computed) | Computed | — | — | Cash 639,545 + equity 1,049,352 + all other 242,094 = 1,930,991, summed across the director compensation table rows.machine: formula: Σ = 1,930,991 |
| 58 | Bicycle Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-22 | 0001104659-26-046806 | CEO total compensation as printed in Bicycle Therapeutics's own proxy. As printed: 6,341,473. Filing ↗machine: t83 · r5 · c14 · span 491024–491033 |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.